Adlai Nortye Raises $53M in Series B

HANGZHOU, China, July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a biopharmaceutical company, announced that it has raised $53 million in a Series B financin... Biopharmaceuticals, Oncology, Venture Capital Adlai Nortye Biopharma, Reolysin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news